Feasibility and tolerability of sintilimab plus anlotinib as the second‐line therapy for patients with advanced biliary tract cancers: An open‐label, single‐arm, phase II clinical trial

• Published in: International journal of cancer Vol. 152; no. 8; pp. 1648 - 1658
• Main Authors: Jin, Shuiling, Zhao, Ruihua, Zhou, Chuang, Zhong, Qian, Shi, Jianxiang, Su, Chang, Li, Qinglong, Su, Xiaoxing, Chi, Huabin, Lu, Xu, Jiang, Guozhong, Chen, Renyin, Han, Jinming, Jiang, Miao, Qiao, Shishi, Liu, Jingjing, Song, Min, Song, Lijie, Du, Yabing, Chang, Zhiwei, Wang, Meng, Dong, Meilian, Zhong, Yali, Yu, Pu, Zhang, Xiaojian, Zong, Hong
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 15.04.2023; Wiley Subscription Services, Inc
• Subjects: advanced biliary tract cancers; anlotinib; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Argonaute 2 protein; Bile Duct Neoplasms - drug therapy; Biliary tract; Biliary tract diseases; Biliary Tract Neoplasms - genetics; Cancer; Cholangiocarcinoma; Clinical trials; Feasibility Studies; Humans; Intestinal microflora; Medical prognosis; Medical research; Metastases; Microbiomes; Patients; phase II study; second line; sintilimab; advanced biliary tract cancers; anlotinib; phase II study; second line; sintilimab

Patients with biliary tract cancer (BTC) were associated with poor prognosis and limited therapeutic options after first‐line therapy currently. In this study, we sought to evaluate the feasibility and tolerability of sintilimab plus anlotinib as the second‐line treatment for patients with advanced...